VEGFA and hereditary elliptocytosis: VEGF binding to Avastin (commercial name of bevacizumab), the first humanized anti-VEGF monoclonal antibody approved by the US Food and Drug Administration for the first-line treatment of metastatic colorectal cancer [29], is significantly enhanced in the presence of HE, with a maximal effect (>2-fold) being observed in the presence of 0.1 μg·mL−1 HE [30].